72 % of doctors advocate for digital therapeutics in diabetes care transformation : Fitterfly whitepaper
Fitterfly , a leading health-tech company working in the field of digital therapeutics ( DTx ), has released a whitepaper on the advocacy of digital therapeutics among clinicians in India . After reviewing 2877 prescriptions from 1897 Fitterfly members , with minimal mention of digital therapeutics as a therapy option , a survey was conducted among clinicians to assess their awareness of this approach . The whitepaper is based on the findings of a comprehensive survey , assessing the usage , prescription guidelines , and outcomes of Digital Therapeutics ( DTx ) in diabetes management . It analyzed the responses of 232 doctors who treat diabetes ( Endocrinologists , diabetologists and physicians ) from 99 cities across India .
Dr Arbinder Singal , CEO , and Co-Founder of Fitterfly , said , “ Digital Therapeutics have an edge in terms of personalized treatment and increased patient engagement leading to superior adherence and outcomes . These are two of the biggest benefits of this tech-driven approach . However , it may be beneficial for HCPs to undergo live online training sessions that can familiarize them with the tools and processes of DTx .”
Sanofi India ’ s Type 1 Diabetes Social Impact Program with RSSDI delivering positive outcomes
HealthTech
Research Society for the Study of Diabetes in India ( RSSDI ) along with Sanofi India Limited ( SIL ) have shared that their collaboration for SIL ’ s social impact program for Type 1 diabetes ( T1D ) is delivering positive outcomes . The program has created a universal standard-of-care for the diagnosis and management of this auto-immune chronic condition , generally impacting the paediatric population and young adults . It also provides funding for free insulin , syringes , lancets , and glucose strips to 1,300 underprivileged children living with this condition . These children are receiving better education on T1D management and have access to insulin ; and are thus demonstrating much improvement in their ability to manage hypoglycaemia and hyperglycaemia . During September 2022 to June 2023 , the program ’ s intervention has reduced the number of children experiencing hypoglycaemia ( 1 to 4 times per week ) by 46 % ( vs . 70 %) and children experiencing hyperglycaemia ( 1 to 4 times per week ) by 25 % ( vs . 52 %).
BIOVOICENEWS . COM 11